MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...
Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme ...
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab). This version, which will be marketed ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) ...
The study demonstrated that Rybrevant Faspro has met co-primary pharmacokinetic endpoints. Credit: Johnson & Johnson / PRNewswire. Johnson & Johnson (J&J) has received the US Food and Drug ...
NEW YORK – The US Food and Drug Administration approved a subcutaneous version of Johnson & Johnson's Rybrevant (amivantamab) for patients with EGFR-mutated non-small cell lung cancer, a year after ...
SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced Thursday that the U.S. Food and Drug Administration has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), a subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback